Biomimetic Targeting and Autonomous Optimization in Nanomedicine

Despite $100 billion in investment and more than 100,000 publications, nanomedicine translation fails primarily at biological validation, not at synthesis or characterization. We present the first systematic technology readiness assessment across autonomous nanomedicine components, revealing a critical finding: while individual technologies achieve TRL 5-8 (commercial organ-chips with 87% sensitivity and 100% specificity for hepatotoxicity; microfluidic platforms processing 96 formulations in 6 hours; nano-QSAR models with 97% cytotoxicity accuracy), closed-loop integration where biological feedback directly informs iterative optimization remains at TRL 2-3. This integration gap, rather than component performance, is the primary barrier to autonomous nanomedicine. We synthesize advances across four pillars into a Design-Make-Test-Biology-Learn (DMTBL) framework that distinguishes physicochemical testing from biological validation, addressing the automation-biology asymmetry where synthesis proceeds at 100-fold human throughput while biological assessment remains manual and temporally decoupled. The framework spans predictive intelligence (PBPK models achieving R^2 = 0.92 for tumor delivery), physical automation (self-driving laboratories), nano-bio interface engineering (protein corona dynamics, complement modulation), and living systems integration (patient organoids with 87% clinical correlation). Three barriers impede integration: temporal mismatch (synthesis in hours versus biology in weeks), data heterogeneity (numerical inputs versus qualitative observations), and biological variability (inter-platform CV > 15%). We identify prerequisites for clinical translation and present a realistic roadmap extending to 2030-2035, distinguishing achievable milestones from aspirational goals. This framework positions autonomous nanomedicine as an actionable research agenda rather than a speculative vision.